Related Experiment Video

Updated: Mar 8, 2026

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

7.5K

Targeting GPCR-Gβγ-GRK2 signaling as a novel strategy for treating cardiorenal pathologies

Valeria Rudomanova1, Burns C Blaxall1

  • 1The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Biochimica Et Biophysica Acta. Molecular Basis of Disease
|January 29, 2017
PubMed

Insights

The cardiorenal syndrome involves heart and kidney dysfunction. Targeting G-protein coupled receptor (GPCR)-Gβγ-GPCR kinase 2 (GRK2) interactions may treat this condition and reduce fibrotic remodeling.

Area of Science:

  • Cardiovascular medicine
  • Nephrology
  • Molecular signaling

Background:

  • Cardiorenal syndrome (CRS) links heart and kidney dysfunction, worsening outcomes.
  • Fibrotic remodeling is central to heart and kidney failure.
  • G-protein coupled receptor (GPCR) signaling regulates cardiovascular and renal functions.

Purpose of the Study:

  • To review the role of GPCR-Gβγ-GRK2 signaling in cardiorenal pathologies.
  • To highlight small molecule inhibitors targeting GPCR-Gβγ-GRK2 interactions.
  • To explore therapeutic potential for cardiorenal diseases.

Main Methods:

  • Review of current literature on GPCR signaling in cardiorenal syndrome.
  • Analysis of the Gβγ-GRK2 interaction in organ remodeling.
  • Discussion of small molecule-based therapeutic strategies.

Main Results:

  • Pathologic GPCR signaling, specifically the Gβγ-GRK2 interaction, drives maladaptive fibrotic remodeling in heart and kidney failure.
  • This interaction mediates receptor internalization, scaffolding, and degradation, contributing to organ dysfunction.
  • Small molecule inhibitors offer a potential strategy to disrupt this pathway.

Conclusions:

  • GPCR-Gβγ-GRK2 signaling is a key mediator of cardiorenal pathologies.
  • Inhibiting this pathway represents a promising therapeutic target for cardiorenal syndrome.
  • Further research into small molecule inhibitors could lead to novel treatments.
Keywords:
Cardiorenal syndromeFibrosisHeart failureKidney injurySignal transduction

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.6K
A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 406:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

14.6K

Related Concept Videos

G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
18.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
8.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.6K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.9K
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
6.2K